6,587 Shares in Danaher Corporation $DHR Bought by Signal Advisors Wealth LLC

Posted by Stanley Muller on Oct 15th, 2026

Signal Advisors Wealth LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the 3rd quarter, Holdings Channel reports. The fund purchased 6,587 shares of the conglomerate’s stock, valued at approximately $1,459,000.

Several other institutional investors also recently modified their holdings of the stock. GEM Asset Management LLC acquired a new position in Danaher in the 3rd quarter worth about $937,000. Copeland Capital Management LLC bought a new position in Danaher in the third quarter valued at about $773,000. Foster Group Inc. acquired a new stake in shares of Danaher during the third quarter valued at about $716,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Danaher during the third quarter valued at about $3,054,000. Finally, Krilogy Financial LLC boosted its stake in shares of Danaher by 104.2% during the third quarter. Krilogy Financial LLC now owns 23,336 shares of the conglomerate’s stock valued at $5,170,000 after purchasing an additional 11,906 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Wall Street Analysts Forecast Growth

DHR has been the topic of several research reports. UBS Group initiated coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price target on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Barclays increased their target price on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Finally, The Goldman Sachs Group raised their price target on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

View Our Latest Report on DHR

Danaher Stock Up 0.8%

Shares of Danaher stock opened at $224.65 on Thursday. The stock’s 50-day moving average is $212.92 and its 200 day moving average is $195.39. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market cap of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.77 earnings per share. Equities research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio is presently 28.42%.

Danaher Company Profile

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.